ISORAY, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

Item 1.01 Entry into a Material Definitive Agreement.

On January 13, 2020, Isoray Medical, Inc. ("Medical"), a wholly owned subsidiary of Isoray, Inc., entered into Amendment to Exhibit A and Amendment No. 2 to Exhibit B (the "Amendment") of its Amended and Restated Manufacturing and Supply Agreement ("Supply Agreement") with GT Medical Technologies, Inc., a Delaware corporation ("GT Tech"), originally dated April 26, 2019. Pursuant to the Supply Agreement, Medical manufactures and supplies a brachytherapy product that incorporates Cesium-131 seeds within customizable carriers for the treatment of brain tumors (the "GammaTile™ Product") for end users designated by GT Tech. Additionally, Medical supplies loose or braided Cesium-131 seeds for brachytherapy brain cancer treatment to GT Tech on a non-exclusive basis. The Amendment modifies the prices to be paid by GT Tech for material, labor, overhead, and Cesium-131 seeds used in the GammaTile™ Product, and separately specifies pricing for additional services.

Item 9.01 Financial Statements and Exhibits.

(d)           Exhibits



  10.1   Amendment to Exhibit A and Amendment No. 2 to Exhibit B of Amended and
       Restated Manufacturing and Supply Agreement, dated effective January 13,
       2020, between Isoray Medical, Inc. and GT Medical Technologies, Inc.
       (confidential portions of the exhibit have been omitted).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses